Oncology is Spherix’s newest franchise, built on the same methodology that has tracked complex, fast-moving markets for more than a decade and applied to a category where the commercial stakes are among the highest in pharma.

Oncology is Spherix’s newest franchise, built on the methodology that has made Spherix a resource in rheumatology, nephrology, and dermatology for over a decade, now applied to multiple myeloma, CLL, NSCLC, and beyond. The franchise is backed by a dedicated research team, an advisory panel of active KOL podium speakers, and a community of practicing oncologists and hematologist-oncologists, verified for specialty and active patient management in the indications Spherix tracks. Spherix oncology data is a go-to resource for leading brands, industry media, and financial analysts covering the space.